A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD114044)

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: October 21, 2010
Last updated: October 23, 2014
Last verified: October 2014

The purpose of this study is to determine whether GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.

Condition Intervention Phase
Muscular Dystrophies
Drug: GSK2402968 6mg/kg/week
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • To assess the efficacy of subcutaneous 6 mg/kg GSK2402968 versus placebo; specifically to have 90% power to detect a difference in 6MWD between GSK2402968 and placebo of 30 meters, assuming a common standard deviation of 55meters [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the safety and tolerability of subcutaneous 6 mg/kg GSK2402968 with respect to AEs, ECG results, vital signs and laboratory tests [ Time Frame: one year ] [ Designated as safety issue: Yes ]
  • Plasma concentration of subcutaneous 6 mg/kg GSK2402968 calculated at each time point for each subject (sample size (n), mean, standard deviation (SD), percentage of coefficient of variation (%CV), geometric mean, median, minimum, and maximum [ Time Frame: one year ] [ Designated as safety issue: No ]
  • To evaluate the difference on quality of life of between GSK2402968 and placebo using PedsQOL, CGI-I and HUI [ Time Frame: one year ] [ Designated as safety issue: No ]

Enrollment: 186
Study Start Date: December 2010
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GSK2402968
Drug: GSK2402968 6mg/kg/week
Experimental: Placebo
Drug: GSK2402968 6mg/kg/week


Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ambulant subjects with Duchenne muscular dystrophy resulting from a mutation/deletion within the DMD gene, confirmed by a state-of-the-art DNA diagnostic technique covering all DMD gene exons, including but not limited to MLPA (Multiplex Ligation-dependent Probe Amplification), CGH (Comparative Genomic Hybridisation), SCAIP (Single Condition Amplification/Internal Primer) or H-RMCA (High-Resolution Melting Curve Analysis), and correctable by GSK2402968-induced DMD exon 51 skipping.
  • Males, aged at least 5 years, and with life expectancy of at least 1 year
  • Able to complete 6MWD test with minimal distance of at least 75m at each predrug visit. In addition, results of 6MWD must be within 20% of each other at each pre-drug visit
  • Receiving glucocorticoids for a minimum of 6 months immediately prior to screening, with no significant change in total daily dosage or dosing regimen for a minimum of 3 months immediately prior to screening and a reasonable expectation that total daily dosage and dosing regimen will not change significantly for the duration of the study
  • QTc <450msec (based on single or average QTc value of triplicate ECGs obtained over a brief recording period), or <480 msec for subjects with Bundle Branch Block. Note: QTc may be either QTcB or QTcF, and machine read or manual overread.
  • Subjects, where appropriate, must be willing to use adequate contraception (condoms or abstinence) for the duration of the study and for at least 5 months after the last dose of study drug.
  • Willing and able to comply with all protocol requirements and procedures,
  • Able to give informed assent and/or consent in writing signed by the subject and/or parent(s)/legal guardian (according to local regulations).
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion Criteria:

  • Any additional missing exon for DMD that cannot be treated with GSK2402968
  • Current or history of liver or renal disease or impairment
  • Acute illness within 4 weeks of the first anticipated administration of study medication which may interfere with study assessments
  • Use of anticoagulants, antithrombotics or antiplatelet agents, previous treatment with investigational drugs, within 6 months of the first administration of study medication; and idebenone or other forms of Coenzyme Q10 within 1 month of the first administration of study medication.
  • Current or anticipated participation in any investigational clinical studies
  • Positive hepatitis B surface antigen, hepatitis C antibody test (if verified via RIBA or PCA testing), or human immunodeficiency virus (HIV) test at screening,
  • Symptomatic cardiomyopathy. If subject has a left ventricular ejection fraction <45% at Screening, the investigator should discuss inclusion of subject in the study with the medical monitor,
  • Children in Care. The definition of a Child in Care is a child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. The definition of a child in care can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a child in care does not include a child who is adopted or has an appointed legal guardian.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01254019

  Hide Study Locations
GSK Investigational Site
Buenos Aries, Buenos Aires, Argentina, C1425AWC
GSK Investigational Site
Leuven, Belgium, 3000
GSK Investigational Site
Curitiba, Paraná, Brazil, 80250-060
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
GSK Investigational Site
Ribeirao Preto, São Paulo, Brazil, 14048-900
GSK Investigational Site
Santo Andre, São Paulo, Brazil, 09060-650
GSK Investigational Site
Rio de Janeiro, Brazil, 21941-490
GSK Investigational Site
São Paulo, Brazil, 05403-900
Canada, British Columbia
GSK Investigational Site
Vancouver, British Columbia, Canada, V6H 3V4
Canada, Ontario
GSK Investigational Site
London, Ontario, Canada, N6A 4G5
Canada, Quebec
GSK Investigational Site
Montreal, Quebec, Canada, H1T 1C9
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7500539
GSK Investigational Site
Santiago, Chile, 8330074
Czech Republic
GSK Investigational Site
Brno, Czech Republic, 613 00
GSK Investigational Site
Praha 5, Czech Republic
GSK Investigational Site
Koebenhavn Oe, Denmark, 2100
GSK Investigational Site
Lille cedex, France, 59037
GSK Investigational Site
Marseille cedex 5, France, 13385
GSK Investigational Site
Nantes cedex 01, France, 44093
GSK Investigational Site
Paris cedex 15, France, 75743
GSK Investigational Site
Toulouse cedex 9, France, 31059
GSK Investigational Site
Freiburg, Baden-Wuerttemberg, Germany, 79106
GSK Investigational Site
Muenchen, Bayern, Germany, 80337
GSK Investigational Site
Goettingen, Niedersachsen, Germany, 37075
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45122
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany, 24105
GSK Investigational Site
Budapest, Hungary, 1095
GSK Investigational Site
Ferrara, Emilia-Romagna, Italy, 44100
GSK Investigational Site
Roma, Lazio, Italy, 00165
GSK Investigational Site
Roma, Lazio, Italy, 00168
GSK Investigational Site
Milano, Lombardia, Italy, 20122
GSK Investigational Site
Messina, Sicilia, Italy, 98125
GSK Investigational Site
Hyogo, Japan, 650-0017
GSK Investigational Site
Kumamoto, Japan, 860-8556
GSK Investigational Site
Saitama, Japan, 349-0196
GSK Investigational Site
Tokyo, Japan, 187-8551
Korea, Republic of
GSK Investigational Site
Seoul, Korea, Republic of, 110-744
GSK Investigational Site
Leiden, Netherlands, 2333 ZA
GSK Investigational Site
Oslo, Norway, 0027
GSK Investigational Site
Warszawa, Poland, 02-097
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 125412
GSK Investigational Site
Esplugues de Llobregat. Barcelona, Spain, 08950
GSK Investigational Site
Madrid, Spain, 28046
GSK Investigational Site
Valencia, Spain, 46026
GSK Investigational Site
Kaohsiung, Taiwan, 80708
GSK Investigational Site
Ankara, Turkey, 06100
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01254019     History of Changes
Other Study ID Numbers: 114044
Study First Received: October 21, 2010
Last Updated: October 23, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Canada: Health Canada
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte
Europe: European Medicines Agency

Keywords provided by GlaxoSmithKline:
Duchenne Muscular Dystrophy

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Muscular Diseases
Muscular Disorders, Atrophic
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases

ClinicalTrials.gov processed this record on March 31, 2015